PALISADE BIO, INC. Royalty Expense
PALISADE BIO, INC. (PALI) reported Royalty Expense of $6.75 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RoyaltyExpense · last filed 2026-08-10
- PALISADE BIO, INC. royalty expense for the quarter ending 2026-06-30 was $0.00.
- PALISADE BIO, INC. royalty expense for the quarter ending 2026-03-31 was $6.75M, a 0.00% change year-over-year.
- PALISADE BIO, INC. royalty expense for the quarter ending 2025-12-31 was $0.00.
- PALISADE BIO, INC. royalty expense for the quarter ending 2025-09-30 was $0.00.
- PALISADE BIO, INC. royalty expense for fiscal 2025 was $6.75M, a 0.00% change from fiscal 2024.
- PALISADE BIO, INC. royalty expense for fiscal 2024 was $6.75M.
- PALISADE BIO, INC. royalty expense for fiscal 2022 was $1.90M, a 0.00% change from fiscal 2021.
- PALISADE BIO, INC. royalty expense for fiscal 2021 was $1.90M.
| Period end | Royalty Expense 3 month | Royalty Expense 6 month | Royalty Expense 9 month | Royalty Expense 12 month | Royalty Expense 36 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $6.75M 10-Q · filed 2026-08-10 | $6.75M derived: sum of 3 quarters · filed 2026-08-10 | $6.75M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | $6.75M 10-Q · filed 2026-05-12 | $6.75M derived: sum of 2 quarters · filed 2026-05-12 | $6.75M derived: sum of 3 quarters · filed 2026-05-12 | $6.75M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $0.00 derived: sum of 2 quarters · filed 2026-03-20 | $0.00 derived: sum of 3 quarters · filed 2026-03-20 | $6.75M 10-K · filed 2026-03-20 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $6.75M 10-Q · filed 2025-11-10 | $6.75M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $6.75M 10-Q · filed 2025-08-11 | $6.75M derived: sum of 3 quarters · filed 2025-08-11 | $6.75M derived: sum of 4 quarters · filed 2025-08-11 | |
| 2025-03-31 | $6.75M 10-Q · filed 2025-05-12 | $6.75M derived: sum of 2 quarters · filed 2025-05-12 | $6.75M derived: sum of 3 quarters · filed 2025-05-12 | $6.75M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $0.00 derived: sum of 2 quarters · filed 2025-03-24 | $0.00 derived: sum of 3 quarters · filed 2025-03-24 | $6.75M 10-K · filed 2025-03-24 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $6.75M 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $6.75M 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $6.75M 10-Q · filed 2024-05-13 | ||||
| 2023-12-16 | $4.50M 10-Q · filed 2026-08-10 | ||||
| 2022-12-31 | $1.90M 10-K · filed 2023-03-22 | ||||
| 2021-12-31 | $1.90M 10-K · filed 2022-03-17 | ||||
| 2018-12-31 | $6.75M 10-K · filed 2024-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |